MarketScreener

Veracyte, Inc. Reports NRG/RTOG 0815 Analysis Shows Decipher Prostate Genomic Classifier Predicts Benefit From Adding Short-Term Androgen Deprivation Therapy To Dose-Escalated ...

Veracyte, Inc. announced that new findings from a retrospective ancillary analysis of the randomized phase III NRG/RTOG 0815 trial will be presented at the 2026 American Society for Radiation Oncology ...
MarketScreener

Phase III Trial Demonstrates Veracyte’s Decipher Prostate Test Predicts Benefit from Adding Hormone Therapy to Radiation

First predictive evidence in intermediate-risk prostate cancer supporting use of the Decipher test to guide short-term hormone therapy decisions to be presented at ASTRO 2026. SOU ...
thecourierexpress.com

Prostate cancer screening: What the numbers mean and when to start

September is Prostate Cancer Awareness Month, highlighting the importance of understanding prostate cancer screenings, ...
The Advocate

Doctor Says: Your PSA is a lot like your golf handicap

For men, taking measure of your prostate health is a lot like tracking your golf games — and just as personal, Dr. Curtis ...
Everyday Health on MSN

How to decode your PSMA-PET scan and track your metastatic prostate cancer treatment progress

Learn how to interpret your PSMA-PET scan results, understand SUV metrics, and track metastatic prostate cancer treatment options and progress.

Should you get a prostate-specific antigen test for prostate cancer?

Prostate cancer is common. About 200 in every 1,000 Australian men will be told they have prostate cancer by age 85. But the ...

Man goes to doctor to prove he’s 'in perfect shape,' test reveals shocking diagnosis

A Louisiana musician's early prostate cancer diagnosis at 33 is now fueling his advocacy for earlier PSA screening despite ...